Clinical trial of novel therapeutic for mild COVID-19 infection to prevent severe disease and reduce viral shedding (Upinder Singh)

Singh’s team is conducting a trial of a novel therapeutic called Lambda, a broad-spectrum anti-viral compound that’s been given to more than 3,000 patients in clinical trials of hepatitis viruses, for efficacy in outpatients with mild COVID-19. In vitro and animal-model data suggest Lambda may also inhibit replication of respiratory viruses, such as the COVID-19 virus. The team plans to perform a phase 2 randomized controlled trial of Lambda among outpatients with mild COVID-19 to determine whether the drug reduces the duration of symptoms, viral shedding and the risk of hospitalization. Stanford Office of Technology Licensing info@otlmail.stanford.edu. 650-723-0651